Phenomenex has launched 2.6µm and 1.7µm EVO C18 particle sizes, expanding the company’s Kinetex core-shell column family. The Kinetex EVO C18 columns provide a unique C18 selectivity offering excellent peak shape for bases, 100 per cent aqueous stability and rugged pH stability from 1 to 12 by incorporating a patented organo-silica grafting process that utilises uniform stabilising ethane cross-linking. Kinetex EVO C18 delivers the performance advantages of Core-Shell Technology at low, neutral and high pH ranges, making it an excellent addition to any lab’s current reversed phase column portfolio.
The new, smaller particle sizes extend the versatility and scalability of this media, which was introduced initially in 5µm particles for HPLC and preparative HPLC work. Overall, Kinetex EVO C18 columns are suitable for virtually every industry that relies on chromatography, including pharmaceutical drug discovery and development, clinical research, forensic toxicology, food safety and quality and environmental analysis.
The rugged EVO C18 columns are an extension of the Phenomenex Kinetex core-shell line, which delivers improved results, increased productivity, easy transferability and significant cost savings compared to traditional HPLC/ UHPLC media. The new 2.6µm EVO C18 columns offer performance comparable to sub-2µm fully porous particles on both standard LC and UHPLC systems, but at lower backpressures. The new 1.7µm particle size is designed for use with UHPLC systems and delivers on average 20 per cent greater efficiencies than fully porous media. Both of these new particle sizes are directly scalable to each other and to the existing 5µm size, making method transfer between UHPLC, HPLC and preparative HPLC techniques straightforward.
Contact Details:
Raj Kiran. CH
Mktg Communication Associate
Phenomenex India
Laxmi Cyber City,
Gr Floor, B Block,
Survey no. 10, Kondapur,
Hyderabad – 500 084 (India)
Tel: 040 – 3012 2400
Fax: 040 – 3012 2411
Email: [email protected]
Website: http://www.phenomenex.com
- Advertisement -
Comments are closed.